AST’s blossoming stent trial
This article was originally published in The Gray Sheet
Executive Summary
Advanced Stent Technologies expects to receive FDA approval to begin enrollment "in the next several months" of up to 100 patients at four to six U.S. sites to study its Petal coronary bifurcation bare-metal stent. The firm received conditional approval for use of Petal and its delivery system in 30 nonrandomized patients in its U.S. BOSS study on Sept. 3. FDA had cleared an investigational device exemption for Petal in December 2001 for a 30-patient feasibility study (1"The Gray Sheet" Sept. 3, 2004, p. 27). AST gained a CE mark for a rapid-exchange version of its SLK-View DSX stent for treating bifurcated lesions in February 2003...
You may also be interested in...
Boston Scientific/ASTI deal targets bifurcated vessels
Purchase of Advanced Stent Technologies, Inc. Dec. 16 will allow Boston Scientific to combine its Taxus paclitaxel-eluting stent technology with ASTI's Petal bifurcation coronary stent design to treat disease in bifurcated vessels, Boston Scientific says. Bifurcated lesions are present in as many as 30% of diseased vessels. A bare-metal Petal has FDA trial go-ahead (1"The Gray Sheet" Sept. 13, 2004, In Brief)...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.